TargetBeta
SLC6A2
solute carrier family 6 member 2 · also NET, NET1, NAT1, SLC6A5 · Solute carrier family 6
6 programs in company-led studies act on SLC6A2, from 6 companies: 1 in phase 3, 5 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (6 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Bupropionrule | GlaxoSmithKline | phase 4 | 291 running | SLC6A3 | ChEMBL |
| lisdexamfetaminerule | Takeda | phase 4 | 470 running | SLC18A2, SLC6A3 | ChEMBL |
| dexmethylphenidaterule | Cingulate Therapeutics | phase 4 | 140 running | SLC6A3 | ChEMBL |
| Levomilnacipranrule | AbbVie | phase 4 | 130 running | SLC6A4 | ChEMBL |
| Amphetaminerule | Tris Pharma | phase 4 | 80 running | SLC6A3 | ChEMBL |
| esreboxetinerule | Pfizer | phase 3 | 82 running | – | ChEMBL |
Conditions their studies are in
- Attention Deficit Disorder with Hyperactivity, 3 programs
- Depressive Disorder, Major, 3 programs
- Binge-Eating Disorder, 1 program
- Depression, 1 program
- Depressive Disorder, 1 program
- Fasting, 1 program
- Fatigue, 1 program
- Fibromyalgia, 1 program
- Ischemic Stroke, 1 program
- Obesity, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2027Bupropion · GlaxoSmithKline · phase 4 · NCT07766655
- Mar 2028esreboxetine · Pfizer · phase 3 · NCT07398417
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.